The thyroid TRK-T3 oncogene results from the fusion of the tyrosine kinase (TK) domain of NTRK1 (one of the receptors for the Nerve Growth Factor) on chromosome 1 to sequences of a novel gene, TFG, on chromosome 3. The 68 kDa TRK-T3 fusion oncoprotein displays a constitutive tyrosine kinase activity resulting in its capability to transform mouse NIH3T3 cells. The TFG portion of TRK-T3 contains a coiled-coil domain most likely responsible for the constitutive, ligand-independent activation of the receptor tyrosine kinase activity. We have previously shown that TRK-T3 oncoprotein forms, in vivo, complexes of three or four molecules. By mean of dierent experimental approaches, we show here that TRK-T3 activity depends on oligomers formation. In addition, the analysis of dierent TRK-T3 mutants indicates that the TFG coiled-coil domain and its Nterminal region are both required for the activation and the fully transforming activity of the TRK-T3 oncoprotein, although, most likely, they play a role in dierent steps of the transforming process. The deletion of the coiled-coil domain abrogates the oligomers formation leading to a constitutive activation; the deletion of the Nterminal region, although not aecting phosphorylation and complexes formation, abrogates transformation, thus suggesting a role in cellular localization and/or interaction with substrata.
Introduction
The thyroid TRK oncogenes are created by chromosomal rearrangements occurring in the thyroid follicular epithelium cells and producing chimeric oncogenes containing the NTRK1 tyrosine-kinase (TK) domain fused to dierent 5' activating sequences (Pierotti et al., 1996 for review) . Previous studies, performed in our laboratory, have shown that TRK activation is achieved by the involvement of three dierent activating sequences: TPM3, TPR and TFG. These genes, as well as the genes activating other receptor tyrosine kinase (RTK)-derived oncogenes, code for proteins sharing some common features: constitutive expression, cytoplasmic localization, presence of dimerization domains. Such properties are conferred to the oncogenes and determine the ectopic expression of the NTRK1 TK domain in the epithelial follicular cells, their cytoplasmic localization and their constitutive, ligand independent activation (Pierotti et al., 1996) . The dimerization domains present in the activating genes are represented by coiled-coil domains. Such motifs consist of heptad repeats of leucine residues over a span of 20 ± 30 amino acids and confer to the protein the capability to fold into a coiled-coil (Lupas et al., 1991; Lupas, 1996) . Computer-assisted sequence analysis has shown the presence of coiled-coil domains in the activating portion of almost all the RTK-derived oncogenes (Rodrigues and Park, 1993) . Such motifs, most likely, promote the self-association of the oncoproteins that triggers the constitutive transautophosphorylation of the tyrosine-kinase domain, thus mimicking the receptor dimerization upon ligand binding. However, the role of coiled-coil domains in oncogenic activation has been documented only for the MET (Rodrigues and Park, 1994 ) and the PTC1 (Tong et al., 1997) oncogenes, whereas it remains inferred but not proved for the other RTK-derived oncogenes, including TRKs.
The TRK-T3 oncogene, detected in a papillary thyroid tumor, is activated by TFG (TRK Fused Gene), a novel gene on chromosome 3. TRK-T3 encodes a 68 kDa cytoplasmic protein displaying a constitutive tyrosine phosphorylation and capable to transform NIH3T3 mouse ®broblasts (Greco et al., 1995) .
The TFG gene encodes a 2.4 kb mRNA expressed in a broad variety of fetal and adult tissues. The predicted amino acid sequence indicated that TFG contains a potential coiled-coil domain that could play an important role in the ligand-independent activation of TRK-T3 oncogene. Based on the sedimentation pro®le on a sucrose density gradient, we have recently shown that the TRK-T3 oncoprotein may form, in vivo, complexes of three or four molecules (Greco et al., 1995) . Recently, the presence of several putative phosphorylation sites for PKC and CK2 has been reported in the TFG portion contained in TRK-T3 (Mencinger et al., 1997) .
The speci®c aims of the present study are: (1) to study in details the previously observed complexes formation capability by mean of dierent experimental approaches; and (2) to precisely de®ne the role of the TFG sequences in TRK-T3 oncogenic activation.
The ability of TRK-T3 to form complexes was demonstrated by several evidences: capability to bind to a GST/TRK-T3 fusion protein; coimmunoprecipitation with a HA-tagged TRK-T3 protein; inhibition of phosphorylation and transforming activity by coexpressing the wild type TRK-T3 and a dominant-negative tyrosine-kinase defective mutant. To study the role of the TFG sequences we have constructed several TRK-T3 mutants involving the coiled-coil as well as the N-terminal region and assayed for the phosphorylation status, the transforming activity and the capability to form complexes. Our results show that TRK-T3 cDNAs carrying point mutations within the coiled-coil domain still retain the capability to form complexes (in our experimental conditions) but show a reduction of both phosphorylation and transformation; the deletion of the same region completely abolishes all the biochemical and biological activity analysed. The deletion of the amino terminal portion does not aect phosphorylation and complexes formation; however, it completely abolishes the TRK-T3 transforming activity. Our data support the model of constitutive activation triggered by a constitutive dimerization of the oncoproteins. Moreover, they suggest an important role also for the regions outside the coiled-coil.
Results

Construction and expression of TRK-T3 mutants
The structure of the wild type and mutated TRK-T3 proteins is shown in Figure 1 . The TRK-T3 cDNA is made of 592 amino acids, 193 of which are encoded by TFG. The coiled-coil domain spans 28 amino acids (from Leu97 to Glu124) (Greco et al., 1995) . The mutant T3/DLeu lacks the coiled-coil domain of TFG; it was constructed by PCR ampli®cation of the two TRK-T3 fragments followed by ligation at a de novo introduced BamHI restriction site. The resulting construct lacks amino acids 98 ± 130, contains a GluSer insertion due to the cloning strategy and encodes a 561 amino acids protein (MW 62 kDa). The T3/L-V and T3/3L-V mutants were constructed by site-directed mutagenesis by which the leucines in position d of the coiled-coil were changed to valine (see Materials and methods). Mutant T3/L-V carries the mutation of the leucine of the central coiled-coil heptad; in T3/3L-V all the three leucine residues were mutated ( Figure 1 ). Mutant T3/DN lacks amino acids 2 ± 90, containing putative phosphorylation sites for PKC and CK2 (Mencinger et al., 1997) ; it was constructed by PCR, as described in Materials and methods and encodes a protein of 503 amino acids (MW 56 kDa). The TRK-T3 mutant constructs were inserted into the PRC/CMV mammalian expression vector; transient transfection into COS1 cells followed by Western blot analysis with NTRK1 antibodies showed that the constructs express proteins of the expected molecular weight (Figure 2a) . To detect the phosphorylation status of the mutated proteins, a twin blot was hybridized with the antiphosphotyrosine antibody. The T3/DLeu, lacking the coiled-coil domain, does not display a detectable phosphorylation (Figure 2b ). With respect to the point mutants, the phosphorylation of T3/L-V is comparable to that of the wild type, whereas that of T3/3L-V is slightly reduced (Figure 2 ). Since mutant T3/L-V resulted not dierent from the wild type from this analysis and from the NIH3T3 transformation assay (see relative section) it has not been considered in other experiments. The T3/DN mutant shows a phosphorylation level comparable to the wild type ( Figure 2) .
TRK-T3 self-association depends on the coiled-coil motif
We have previously shown that TRK-T3 may form, in vivo, complexes of three or four molecules, based on the sedimentation pro®le on a sucrose density gradient (Greco et al., 1995) . To study more in detail this feature we used several dierent approaches, based on in vitro binding, coimmunoprecipitation with an epitope-tagged construct, and in vitro and in vivo inhibition by a dominant-negative tyrosine-kinase defective mutant.
For the in vitro binding assay we constructed a GST/TRK-T3 fusion protein (see Materials and methods), containing the TRK-T3 oncoprotein from amino acid 23 to the carboxyl terminus fused in frame to the glutathione-S-transferase. The 92 kDa GST/ TRK-T3 fusion protein, designated as GST/T3, was puri®ed by anity chromatography on glutathioneagarose (data not shown). The wild type TRK-T3 protein was then translated in vitro in the presence of [ 35 S]methionine using plasmid pT3E19A; the speci®city of the translation product was demonstrated by immunoprecipitation with TRK-speci®c antibody (Figure 3a ). After incubation with the GST/T3 fusion protein conjugated to glutathione-sepharose beads, the 35 S-labeled TRK-T3 protein was eluted from the The expanded region at the bottom shows the sequence of the coiled-coil with its corresponding heptad frame; the core three heptads are boldfaced (Greco et al., 1995) TRK-T3 oncogene structure/function analysis A Greco et al complex, thus reproducing in vitro the previously observed capability to form oligomers. The self-association capability was also demonstrated by coimmunoprecipitation experiments using a HA-tagged TRK-T3 protein. The TRK-T3 cDNA was inserted into the pcDNA/HA vector containing three copies of the HA epitope; the resulting construct, pHA/T3, encodes a 71 kDa protein with the HA epitopes at its N-terminal, that reacts with both the anti-HA and the anti TRK antibodies in Western blot analysis ( Figure 4 ). The wild type and the HA-tagged TRK-T3 constructs were transiently co-transfected into We also tested the eect of a dominant-negative tyrosine-kinase defective TRK-T3 mutant on the wild type TRK-T3 activity. The lysine residue of the ATP binding site (Lys309 (Greco et al., 1995) , corresponding to Lys538 of the NTRK1 receptor (Martin-Zanca et al., 1989)) was changed to alanine by site-directed mutagenesis. This mutation has been shown to produce a kinase-defective receptor with a dominant-negative eect on the wild type counterpart (Jing et al., 1992) . Western blot analysis of the kinase-defective TRK-T3 cDNA (plasmids pT3/ABN, two independent clones) expressed into COS1 cells revealed that, as expected, the relative protein was unphosphorylated ( Figure 5 ). When the mutant was coexpressed with the wild type TRK-T3 cDNA, a reduced steady-state phosphorylation level of the TRK-T3 protein was observed ( Figure  5 ), thus indicating that TRK-T3 phosphorylation requires the formation of complexes. The biological signi®cance of these results was determined by NIH3T3 transfection/focus formation assay. Three independent clones of the kinase-defective mutant were transfected alone or in combination with the wild type pT3E19A plasmid. All the plasmid produced G418 resistant colonies with a comparable eciency (data not shown). As shown in Table 1 and Figure 6 , the pT3E19A produced multiple foci, whereas cells transfected with pT3/ABNs did not exhibit detectable levels of morphological transformation. However, when cotransfected with the wild type cDNA, the mutant plasmids inhibited the TRK-T3 transformation of 65 ± 88% (Table 1 and Figure 6 ). These results are compatible with the formation of hetero oligomers involving wild type and mutated TRK-T3 molecules and thus indicate that formation of complexes is a functional requirement for TRK-T3 transforming activity.
To test the eect of the TFG mutations on the TRK-T3 self-association capability, all the in vivo and in vitro assays described above were performed with the TRK-T3 mutants. 35S-methionine-labeled T3/3L-V and T3/DLeu proteins were incubated with the GST/ T3 fusion protein conjugated to the glutathioneagarose: as shown in Figure 3b , a binding activity was detected for T3/3L-V and T3/DN but not for T3/ DLeu. In keeping with this result, cotransfection of T3/ HA and TRK-T3 mutants followed by Western blot analysis as above described, showed that T3/3L-V but not T3/DLeu coimmunoprecipitates with HA/T3 (Figure 4) indicating that the complex formation capability is retained by the point mutant but is lost Both the N-terminal region and the coiled-coil domain are required for TRK-T3 transforming activity
To determine the role of self-association in TRK-T3 oncogenic activation, we examined the transforming activity of wild type and mutant TRK-T3 cDNAs upon transfection into NIH3T3 cells. All the TRK-T3 expression plasmids produced G418-resistant colonies with comparable eciency (data not shown). With respect to the transforming eciency, the wild type and the T3/L-V mutant produced numerous foci after 2 weeks of selection; however, at the same time, the T3/ 3L-V mutant produced small-size, barely visible foci ( Figure 7 and Table 2 ). The T3/3L-V transforming eciency, calculated from plated ®xed after 3 weeks of selection, resulted 1/6 of that of the wild type (Table 2) . Thus, T3/3L-V produced foci with eciency and growth rate reduced with respect to the wild type. The transfection of T3/DLeu and T3/DN did not produce transformed foci. Moreover, individual G418-resistant colonies expressing considerable amount of the mutated proteins ( Figure 2c ) display a nontransformed phenotype (data not shown), ruling out the possibility that the lack of transformation could be ascribed to a low expression of the mutated TRK-T3 proteins. Thus, mutations or deletion of the coiled-coil motif as well as deletion of the N-terminal region aect the transforming activity of TRK-T3 oncoprotein, suggesting a crucial role of these regions in the biological activity of TRK-T3.
Discussion
In the present study we have analysed the capability of TRK-T3 oncoprotein to form complexes and the role of TFG sequences, in particular the coiled-coil domain, in this process and in cell transformation. Previously, we have reported that TRK-T3 may form, in vivo, complexes of three or four molecules, based on the sedimentation pro®le on a sucrose density gradient (Greco et al., 1995) . In the present paper we have reported experimental evidences strongly supporting the previous observation; we have identi®ed the coiledcoil domain as the element conferring the oligomerization capability and shown that it is necessary for TRK-T3 transforming activity. However, oligomerization per se is not sucient; other mechanisms, mediated by a region outside the coiled-coil, play a role in the full oncogenic activation of TRK-T3. We have expressed the TRK-T3 oncoprotein in bacteria, as a GST/TRK-T3 fusion protein; by an in vitro assay we demonstrate its ability to bind to the 35 Slabeled oncoprotein. Similarly, we have shown that the TRK-T3 oncoprotein coimmunoprecipitates with a HA-epitope-tagged TRK-T3 protein. Moreover, when the wild type was coexpressed with a kinase-defective TRK-T3 mutant, a reduction of phosphorylation level and transforming activity was observed. Altogether these results demonstrate that TRK-T3 forms com- NIH3T3 transfection was performed as described in Materials and methods. Plates were ®xed and stained as the indicated times. sf=small foci TRK-T3 oncogene structure/function analysis A Greco et al plexes in vivo. This feature is common to several fusion oncoproteins, derived from receptor and non-receptor tyrosine kinases, in which the complexes formation is mediated either by coiled-coil or by other dimerization domains (McWhirter et al., 1993; Golub et al., 1996; Carroll et al., 1996; Tong et al., 1997) . The number of TRK-T3 molecules involved in a complex remains to be determined; the in vitro binding and the coimmunoprecipitation experiments are not informative on this point. The data produced by the sucrose gradient sedimentation pro®le would suggest a complex of three or four molecules (Greco et al., 1995) . It has been reported that coiled-coils can form dimers, trimers and tetramers (Harbury et al., 1993) . The coiled-coil domain of the BCR/ABL oncogene has been shown to promote tetramerization (McWhirter et al., 1993) . Moreover, a four molecules arrangement is compatible with a recently proposed model for receptor tyrosine kinase activation. Based on crystallographic studies Mohammadi et al. (1996) have proposed that receptors autophosphorylation would occur between dimers rather than within a dimer, thus requiring the occurrence of high order receptor oligomerization. However, the determination of the precise number of molecules involved in the TRK-T3 complex requires speci®c experimental approaches and it is not mandatory for the present work.
In order to study the role of the TFG sequences, in particular the coiled-coil domain, in the TRK-T3 complexes formation and oncogenic activation, we have constructed four mutants: the ®rst one lacks the coiled-coil domain; in the second one the leucine in position d of the central heptad of the coiled-coil was mutated to valine; in the third one the three leucines in position d were mutated; the fourth one carries the deletion of the 89 amino acids preceding the coiledcoil. In vitro binding and coimmunoprecipitation experiments indicate that the deletion of the coiledcoil domain abolishes the capability to form complexes, while the point mutations and the amino terminal deletion do not have any detectable eect.
The role of the N-terminus and of the coiled-coil domain on the transforming activity was investigated by NIH3T3 transfection/focus formation assay. No transforming activity was detected for the T3/DLeu and T3/DN mutants. The T3/L-V point mutant displays a transforming activity comparable to that of the wild type, whereas the T3/3L-V mutant transforms NIH3T3 cells with an eciency and a growth rate reduced with respect to the normal counterpart. Taken together, these results indicate that both the coiled-coil domain and the N-terminal region play a crucial role in the transforming capability of TRK-T3 oncogene, but they are involved in dierent steps. The coiled-coil is involved in the formation of complexes; the N-terminal region could be responsible for the cellular localization of the oncoprotein as well as for its interaction with speci®c substrata. In this context, it is worth mentioning that the full transforming activity of BCR/ABL requires the presence of a region containing a SH2 domain, in addition to the oligomerization domain (McWhirter et al., 1993) . However, the sequence of the TFG amino terminal region revealed the presence of PKC and PK2 phosphorylation sites (Mencinger et al., 1997) but not SH2 docking sites or proline-rich regions. Therefore, understanding the precise role of TFG N-terminal region requires further investigations.
The reduced transforming activity of the T3/3L-V mutant suggests that although the introduced mutations do not disrupt coiled-coil interaction, they interfere with its stability. In this contest, it should be noted that the in vitro binding and the coimmunoprecipitation experiments, using the wild type and the mutated protein, are not suitable for pointing out a dierent strength of interaction caused by the introduced mutations. Interestingly, the same leucine to valine mutations, introduced into one of the coiledcoil domains of the MET oncogene, inhibited the dimerization and transforming activity (Rodrigues and Park, 1993) . The eect of the leucine to valine substitutions introduced in two dierent coiled-coils (TPR and TFG) indicates dierent strength of interaction related to the amino acids composition. We have previously reported that the presence of only hydrophobic residues in position a of the TFG coiledcoil should increase its predicted stability of association (Greco et al., 1995) .
In conclusion, we have demonstrated that the TRK-T3 transforming potential depends on the complexes formation capability triggered by the coiled-coil domain. Several examples of oncogenic activation mediated by oligomerization have been reported. The BCR/ABL and the TEL/ABL oncoproteins, derived from the activation of the non-receptor-tyrosine kinase by the BCR and the TEL proteins, respectively, have been shown to form oligomers mediated by a coiled-coil domain (BCR/ABL) (McWhirter et al., 1993) and by a helix ± loop ± helix domain (TEL/ABL) present in their relative activating portion. In addition, the TEL helix ± loop ± helix motif promotes also the self-association and activation of the TEL/ PDGFR oncogene (Carroll et al., 1996) . Furthermore, the oncogenic potential of the MET oncogene depends on dimerization mediated by the coiled-coil domain within TPR (Rodrigues and Park, 1994) ; the mitogenic activity of the ret/ptc2 oncogenes requires the dimerization domain of the RIa activating gene (Durick et al., 1995) . Recently Tong et al. (1997) have reported that dimerization, mediated by a leucine zipper motif, is essential for the PTC1 oncogenic activity.
Thus, the complexes formation is a mechanism of activation common to a growing group of oncogenes derived from tumor-associated tyrosine kinase rearrangements. However, the lack of transforming activity in the presence of phosphorylation showed by mutant lacking the N-terminus suggests that other mechanisms, beside complexes formation, play a role in conferring the full oncogenic potential.
Materials and methods
Cell culture and transfection
Mouse NIH3T3 ®broblasts and monkey COS-1 cells were maintained in Dulbecco's modi®ed Eagle's medium supplemented with 10% calf serum and 10% fetal calf serum, respectively. NIH3T3 cells (2.5610 5 /10 cm plate) were transfected by the CaPO 4 method as previously described (Bongarzone et al., 1989) , using 10 ± 500 ng of plasmid DNA together with 30 mg of mouse DNA. Transformed foci were selected in DMEM containing 5% TRK-T3 oncogene structure/function analysis A Greco et al serum; G418-resistant colonies in DMEM plus 10% serum and G418 antibiotic (500 mg/ml). Transformed foci and G418-resistant colonies were either ®xed or isolated for further studies 2 or 3 weeks after transfection. COS-1 cells were transfected by the DEAE-dextran-chloroquine treatment (Luthman and Magnusson, 1983) . Exponentially growing cells (10 6 /10 cm plate) were incubated with 2 ml of serum-free medium containing 300 ng of DEAE-dextran and 2 ± 10 mg of plasmid DNA for 30 min at 378C. After three washes with serum-free medium the cells were treated with 10 mM chloroquine in medium supplemented with 10% serum for 3 h. Afterwards cells were reefed with 10%-serum medium, incubated for 2 ± 3 days and then processed for protein extraction.
Western blot analysis
Cell lysates were prepared as described elsewhere (Borrello et al., 1994) . After immunoprecipitation with the indicated antibody, the protein samples were electrophoresed on a sodium-dodecyl-sulfate (SDS)-polyacrylamide gel, (8.5%), transferred to nitrocellulose ®lters, and immunoblotted with the indicated antisera. Immunoreactive bands were visualised by using horseradish peroxidase-conjugated secondary antiserum and enhanced chemiluminescence (Amersham).
The polyclonal NTRK1-speci®c antibody has been previously described (Borrello et al., 1994) ; the anti-HA monoclonal antibody was kindly provided by Dr K Helin; the monoclonal antiphosphotyrosine antibody was purchased from Upstate Biotechnology Incorporated.
Plasmid construction
The construction of the pT3E19A, containing the fulllength TRK-T3 cDNA inserted into the pRC/CMV expression vector, has been previously reported (Greco et al., 1995) . All the point mutants were constructed by sitedirected mutagenesis using an in vitro oligonucleotide mutagenesis system (Altered Sites in vitro Mutagenesis System, Promega). To construct mutant T3/L-V the Leucine in position 112 was changed to Valine using the oligonucleotide AG3970 (5'-ATTTCGAACTTCTATCA-3'). Mutant T3/3L-V was constructed from T3/L-V using simultaneously oligonucleotides AG3969 (5'-TCGACGGA-CATATTTCA-3') and AG3971 (5'-CTATCCAATACAC-GATTCAC-3') carrying the mutations of Leucines 105 and 119, respectively. The T3/ABN mutant was constructed using nucleotide AG4572 (5'-CTTCTTCAGTGCCGCGA-CAGCCACCAGC-3', oligonucleotides 1020 ± 1047) carrying the mutation of the ATP binding site Lysine 309 to Alanine. Mutant clones were identi®ed by PCR followed by allele-speci®c oligonucleotide (ASO) hybridization. Clones positive by these analyses were subjected to nucleotide sequence; selected clones were transferred into the PRC/CMV expression vector.
The T3/DLeu mutant was constructed by PCR amplification followed by DNA ligation. The 5' moiety was ampli®ed using oligonucleotides AG3055 (5'-ATCCTGGAGTCCAC-CATG-3', nucleotide 4 ± 21 of the cDNA) and AG3056 (5'-TAATAGGATCCAAGGGGTCTTGGCTGGCC-3', nucleotides 292 ± 309 followed by a tail carrying the BamHI restriction site). The 3' moiety was ampli®ed using oligonucleotide AG3057 (5'-ATTATGGATCCCCTTCCAC-CAATATT-3', nucleotides 409 ± 423 preceded by a tail including the BamHI restriction site) and nucleotide AG2964 (5'-TTTTTTTTCAAGGGATAATAAA-3', nucleotides 1988 ± 2010). The ampli®ed fragments were cloned into the pGEMT vector to produce the pGT3/5' and pGT3/3' plasmids, respectively and subjected to nucleotide sequence. The 5' fragment was excised from plasmid pGT3/5' by BamHI/NotI digestion and was inserted into the pGT3/3' plasmid linearized with the same restriction enzymes. The resulting plasmid (pGT3DLeu) carries the deletion of nucleotides 309 ± 408. After nucleotide sequence the deleted TRK-T3 cDNA was excised from plasmid pGT3/DLeu by ApaI/NotI digestion and inserted into the pRC/CMV vector linearized with the same restriction enzymes, to produce pT3/ DLeu.
The T3/DN mutant was constructed by PCR ampli®cation. The oligonucleotides utilised were AG3046 (5'-ATCCTG-GAGTCCACCATGAATGGCCAGCCAAGACC-3', containing nucleotides 4 ± 21 fused to nucleotides 289 ± 305 of the cDNA) and AG2964 (5'-TTTTTTTTCAAGGGATAA-TAAA-3', nucleotides 1988 ± 2010). The ampli®ed fragment was introduced into pGEMT vector, subjected to nucleotide sequence, excised by ApaI/NotI digestion and inserted into pRC/CMV expression vector carrying identical ends. The resulting construct encodes a protein in which the initiation codon is followed by Asn 91.
To construct the GST/T3 plasmid the 2043 bp EcoRI fragment (from nucleotide 87 to the 3' end of the cDNA) was excised from plasmid PCRT3 and inserted into the EcoRI site of the pGEX4T-2 vector, in frame with the GST protein translation.
For the pHA/T3 expression vector the pcDNA3/HA plasmid (kindly provided by Dr JC Reed), carrying three HA epitopes was used. The construction included several steps, as follows. A 5'-end fragment was produced by PCR ampli®cation using oligonucleotides AG4212 (5'-ATTAT-GGATCCCGGGGAACGGACAGTTGGA -3', nucleotides 21 ± 35 of the cDNA preceded by a tail containing BamHI and SmaI restriction sites) and AG3056 (5'-TAATAGGATC-CAAGGGGTCTTGGCTGGCC-3', nucleotides 291 ± 309). The ampli®ed 313 bp fragment was inserted into the pGEMT plasmid vector to produce plasmid pG5'313 that was sequenced to verify the absence of any mutation introduced by the Taq polymerase. Plasmid pG5'313 was then digested with PstI and EcoRI, cutting in the insert and in the vector sequences, respectively. This digestion produces a linear vector containing the ®rst 100 nucleotide of the ampli®ed fragment that was isolated. After blunting the PstI end with Klenow DNA polymerase, the linear plasmid was ligated with the 2043 bp EcoRI/XbaI blunt TRK-T3 fragment isolated from the PRC T3 expression plasmid. The resulting pGT3/NT plasmid contains a TRK-T3 cDNA lacking the ATG starting codon that was isolated by digesting with SmaI and XhoI and ligated to the pcDNA3/ HA vector carrying EcoRI/blunt and XhoI ends. The resulting pHA/T3 plasmid contains the TRK-T3 sequences fused in frame with the HA translation and encodes a protein of predicted molecular weight 71 kDa.
DNA sequencing
Nucleotide sequence was determined by the dideoxy chain terminator method (Sanger and Nicklen, 1977) using the sequenase kit (US Biochemical).
In vitro translation
The TRK-T3 wild type and mutated cDNAs cloned into pGEM3 or pRC/CMV vectors were subjected to in vitro transcription-translation using the TNT coupled reticulocyte lysate system (Promega), according to the manufacturer's speci®cation. The proteins were labeled with 35 Smethionine; reactions were performed in a volume of 50 ml, using 1 mg of plasmid DNA as template.
Expression and puri®cation of GST/T3 fusion protein Escherichia coli BL21 strain was transformed with the pGEX-2T and the pGST/T3 plasmids. An overnight culture of these bacteria was diluted 1 : 10 with fresh LB TRK-T3 oncogene structure/function analysis A Greco et al medium plus ampicillin and grown at 378C until OD41. Induction was performed by adding isopropylthiogalactoside (IPTG) to 0.06 mM and incubating at 308C for 2 h. The induced bacteria were pelleted, washed once with 1/5 volume of STE (10 mM Tris, pH 8, 150 mM NaCl, 1 mM EDTA) and resuspended in an equal volume of STE containing 100 mg/ml of lysozime. After incubation on ice for 15 min, DTT (5 mM) and Sarkosyl (1.5%) were added. The cells were lysate by sonication. The lysates were centrifuged at 15 000 g for 5 min. The supernatant was utilized for gel analysis, immunoprecipitation or in vitro binding assay.
In vitro binding assay
The GST/T3 fusion protein extracted from 5 ml of bacteria culture was incubated with glutathione-sepharose (Pharmacia) for 30 min. After centrifugation the complexes were washed three times with lysis buer (STE, 5 mM DTT, 1.5% sarkosyl) and once with PLCLB (50 mM HEPES (pH 7.5), 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 1 mM EGDTA, 100 mM Na 4 P 2 O 7 , 100 mM NaF). The glutathione-sepharose-conjugated GST/T3 fusion protein was incubated with 25 ml of in vitro translated TRK-T3 proteins in 100 ml of PLCLB at 48C for 2 h. The complexes were washed 3 ± 4 times with HNTG (20 mM HEPES, 150 mM NaCl, 10% glycerol, 0.1% Triton X-100). The bound proteins were eluted from the complexes by boiling in Laemly buer (Laemmli, 1970) and resolved on 8.5% polyacrylamide gel. After ®xing in 30% methanol, 7% acetic acid the gel was treated with 1 M salicyclic acid, sodium salt for 30 min and dried. Autoradiography was performed after overnight exposure to Hyper®lm.
